Cholesterol is a significant risk factor for non-alcoholic steatohepatitis

被引:31
|
作者
Walenbergh, Sofie M. A. [1 ]
Shiri-Sverdlov, Ronit [1 ]
机构
[1] Maastricht Univ, Sch Nutr & Translat Res Metab NUTRIM, Dept Mol Genet, Maastricht, Netherlands
关键词
cholesterol; inflammation; lipids; liver; non-alcoholic steatohepatitis; FATTY LIVER-DISEASE; HEPATIC GENE-EXPRESSION; DIETARY-CHOLESTEROL; INFLAMMATION; NASH; MICE; ACCUMULATION; STEATOSIS; ATHEROSCLEROSIS; FIBROSIS;
D O I
10.1586/17474124.2015.1092382
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Non-alcoholic steatohepatitis (NASH) is characterized by hepatic lipid accumulation (steatosis) and inflammation (steatohepatitis). Currently, the exact underlying mechanisms leading to hepatic inflammation remain incompletely understood and therefore therapy options are poor. Analogous to the predominant metabolic risk factor for the metabolic syndrome, NASH patients often display diet-induced dyslipidemia and are therefore also at high risk for cardiovascular disease. Higher lipid levels, in general, are also widely associated with the production of reactive oxygen species during oxidation. However, the exact contribution of the specific type of lipids to hepatic inflammation still remains unclear. In this editorial, we aim to show that cholesterol, in addition to triglycerides and free fatty acids, is an important risk factor in NASH disease pathogenesis. Developing a better understanding of the contribution of lipids underlying NASH pathogenesis is essential for creating effective therapies against this prevalent disease. © 2015 Taylor & Francis.
引用
收藏
页码:1343 / 1346
页数:4
相关论文
共 50 条
  • [21] Non-alcoholic Steatohepatitis (NASH) and alcoholic Steatohepatitis (ASH)
    Roeb, Elke
    DRUG RESEARCH, 2021, 71 : S16 - S18
  • [22] Fibroblast growth factor 21 for non-alcoholic steatohepatitis
    Wong, Vincent W. S.
    Adams, Leon A.
    LANCET, 2018, 392 (10165): : 2658 - 2660
  • [23] Treatment of alcoholic and non-alcoholic steatohepatitis
    Stremmel, W
    Blechacz, B
    Herrmann, T
    Rost, D
    Mueller, S
    INTERNIST, 2001, 42 (12): : 1641 - +
  • [24] Combined alcoholic and non-alcoholic steatohepatitis
    Wandji, Line Carolle Ntandja
    Gnemmi, Viviane
    Mathurin, Philippe
    Louvet, Alexandre
    JHEP REPORTS, 2020, 2 (03)
  • [25] Risk Factors of Non-alcoholic Steatohepatitis in Childhood Obesity
    Yun, Eun Sil
    Park, Yong Hun
    Choi, Kwang Hae
    PEDIATRIC GASTROENTEROLOGY HEPATOLOGY & NUTRITION, 2007, 10 (02) : 179 - 184
  • [26] Statin use and non-alcoholic steatohepatitis in at risk individuals
    Dongiovanni, Paola
    Petta, Salvatore
    Mannisto, Ville
    Mancina, Rosellina Margherita
    Pipitone, Rosaria
    Karja, Vesa
    Maggioni, Marco
    Kakela, Pirjo
    Wiklund, Olov
    Mozzi, Enrico
    Grimaudo, Stefania
    Kaminska, Dorota
    Rametta, Raffaela
    Craxi, Antonio
    Fargion, Silvia
    Nobili, Valerio
    Romeo, Stefano
    Pihlajamaki, Jussi
    Valenti, Luca
    JOURNAL OF HEPATOLOGY, 2015, 63 (03) : 705 - 712
  • [27] Association of non-alcoholic steatohepatitis without significant fibrosis with hepatocellular carcinoma
    Bullock, RE
    Zaitoun, AM
    Aithal, GP
    Ryder, SD
    Beckingham, IJ
    Lobo, DN
    JOURNAL OF HEPATOLOGY, 2004, 41 (04) : 685 - 686
  • [28] Drugs and non-alcoholic steatohepatitis
    Farrell, GC
    STEATOHEPATITIS (NASH AND ASH), 2001, 121 : 132 - 139
  • [29] Obesity and non-alcoholic steatohepatitis
    García-Monzón, C
    STEATOHEPATITIS (NASH AND ASH), 2001, 121 : 117 - 123
  • [30] Saroglitazar for non-alcoholic steatohepatitis
    Baker, Holly
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (09): : 698 - 698